Double Autografting: A Potential Curative Regimen for Acute Leukaemia?

  • C. C. Anderson
  • D. C. Linch
  • A. H. Goldstone
Part of the Developments in Oncology book series (DION, volume 45)


The conditioning regime used for allogeneic bone marrow transplantation in acute leukaemia has two functions: firstly to serve as immunosuppressive therapy to prevent rejection of the allogeneic marrow and secondly to eradicate host disease. The conditioning regimen most commonly used is TBI given as a single dose or in fractions to a total dose of 9–12 Grays together with cyclophosphamide 60mg/kg on two consecutive days as pioneered by the Seattle transplant unit, (Thomas et al, 1975).


Complete Remission Acute Myeloid Leukaemia Acute Lymphoblastic Leukaemia Acute Leukaemia Allogeneic Bone Marrow Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson CC, Goldstone AH, Linch DC, Jones M, Cawley JC, Franklin IM, Boughton BJ & Richards JDM: Autografting for patients with acute myeloid leukaemia and acute lymphoblastic leukaemia: A comparison. (In preparation), 1985.Google Scholar
  2. 2.
    Applebaum FR, Clift RA, Thomas ED, Buckner D, Stewart P, Storb R & Sullivan KM, 1983. Allogeneic marrow transplantation for acute non-lymphocytic leukaemia after first relapse. Blood, 61, 949–954.Google Scholar
  3. 3.
    Burnett AK, Watkins R, Mahara J D, McKinnon S, Tansey P, Alcorn M, Singer CRJ, McDonald GA & Robertson AG: Transplantation of unpurged autologous bone marrow in acute myeloid leukaemia. Lancet, ii, 1068–1070, 1984.CrossRefGoogle Scholar
  4. 4.
    Deeg HJ, Storb R & Thomas ED: Bone marrow transplantation: A review of delayed complications. British Journal of Haematology, 57, 185–208, 1984.PubMedGoogle Scholar
  5. 5.
    Douay L, Gorin NC, Lopez M, Laporte JP, Baillou CL, Leguen MC, Bardinet D, Najman A. & Duhamel G: Study of Asta Z 7557 on human haemopoietic stem cells. Application to autologous bone marrow transplantation. Experimental Haematology, 12, (Suppl. 15), 135–136, 1984.Google Scholar
  6. 6.
    Gorin NC, Aegerter P. & Parlier Y: Autologous bone marrow transplantation for acute leukaemia in remission: Second European survey. Experimental Haematology, (Suppl.), in press, 1985.Google Scholar
  7. 7.
    Laporte JP, Gorin NC, Lopez M, Salmon Ch, Najman A & Duhamel G: Autologous bone marrow transplantation, (ABMT), with marrow purged by Asta Z 7557 as consolidation therapy for acute leukaemias in first remission. Experimental Haematology, 12 (6), 412, 1984.Google Scholar
  8. 8.
    Linch DC, Knott LJ, Patterson KG, Cowan DA & Harper PG: Bone marrow processing and cryopreservation. Journal of Clinical Pathology, 35, 186–190, 1982.PubMedCrossRefGoogle Scholar
  9. 9.
    Maraninchi D, Gastaut JA, Herve P, Flesch M, Mascret B, Sebahoun G, Tubiana N, Novakovitch G & Carcassonne Y: High dose Melphalan and autologous marrow transplantation in acute leukaemias in relapse or remission. Experimental Haematology, 12, (Suppl. 15), 130–131, 1984.Google Scholar
  10. 10.
    O’Reilly RJ: Allogeneic bone marrow transplantation: Current status and future directions. Blood, 62 (5), 941–964, 1983.PubMedGoogle Scholar
  11. 11.
    Ritz J & Schlossman SF: Utilization of monoclonal antibodies in the treatment of leukaemia and lymphoma. Blood, 59, 111, 1982.Google Scholar
  12. 12.
    Souhami RL, Finn G, Gregory WM, Birkhead BG, Buckman R, Edwards D, Goldstone AH, Harper PG, Spiro SG, Tobias JS & Geddes D: High dose cyclophosphamide in small cell carcinoma of the lung. Journal of Clinical Oncology, 3 (7), 958–963.Google Scholar
  13. 13.
    The Medical Research Council’s working party on leukaemia in childhood: The treatment of acute lymphoblastic leukaemia, (ALL), in childhood, UKALL III: The effects of added cytosine arabinoside and/or asparaginase, and a comparison of continuous or discontinuous mercaptopurine in regimens for standard risk ALL. Medical Paediatric Oncology, 10 (5), 501–510, 1982.CrossRefGoogle Scholar
  14. 14.
    The Medical Research Council’s working party on leukaemia in childhood: Duration of chemotherapy in childhood acute lymphoblastic leukaemia. Medical Paediatric Oncology, 10 (5), 511–520, 1982.Google Scholar
  15. 15.
    Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H & Buckner CD: Bone marrow transplantation. New England Journal of Medicine, 292, 832–843, 895–902, 1975.PubMedCrossRefGoogle Scholar
  16. 16.
    Thomas ED, Sanders JE, Flournoy N, Johnson FL, Buckner CD, Clift RA, Fefer A, Goodell BW, Storb R & Weiden PL: Marrow transplantation for patients with acute lymphoblastic leukaemia: A long-term follow-up. Blood, 62, 1139–1141, 1983.PubMedGoogle Scholar
  17. 17.
    Thomas ED: Marrow transplantation for malignant disease. Journal of Clinical Oncology, 1 (19), 517–531, 1983.PubMedGoogle Scholar
  18. 18.
    Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED:: Antileukaemic effect of graft-versus-host disease contributes to improved survival afer allogeneic marrow transplantation. Transplantation Proceedings, 13, 248–251, 1981.PubMedGoogle Scholar
  19. 19.
    Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM & Gelber RD: Chemotherapy for acute myelogenous leukaemia in children and adults: VAPA update. Blood, 62 (2), 315–319, 1983.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Dordrecht 1986

Authors and Affiliations

  • C. C. Anderson
    • 1
  • D. C. Linch
    • 1
  • A. H. Goldstone
    • 1
  1. 1.Bloomsbury Transplant TeamUK

Personalised recommendations